26 articles for W Du
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
SAR exploration at the C-3 position of tetrahydro-ß-carboline sstr3 antagonists.
Merck Research Laboratories
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes.
Merck Research Laboratories
Investigation of Cardiovascular Effects of Tetrahydro-ß-carboline sstr3 antagonists.
Merck Research Laboratories
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes.
TBA
Potent and selective alpha-ketoheterocycle-based inhibitors of the anandamide and oleamide catabolizing enzyme, fatty acid amide hydrolase.
The Scripps Research Institute
Synthesis and evaluation of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-aminopropanamide as human cannabinoid-1 receptor (CB1R) inverse agonists.
Merck Research Laboratories
Discovery of 5-trifluoromethyl-2-aminopyrimidine derivatives as potent dual inhibitors of FLT3 and CHK1.
Zhejiang University
Discovery of a potent and selective proteolysis targeting chimera (PROTAC) degrader of NSD3 histone methyltransferase.
Shanghai Institute of Materia Medica
Preventing Influenza A Virus Infection by Mixed Inhibition of Neuraminidase and Hemagglutinin by Divalent Inhibitors.
Utrecht University
Discovery of a potent, selective, and efficacious class of reversible alpha-ketoheterocycle inhibitors of fatty acid amide hydrolase effective as analgesics.
The Scripps Research Institute
Benzylaminofentanyl derivates: Discovery of bifunctional μ opioid and σ
Jiangsu Ocean University
Discovery of an exceptionally potent and selective class of fatty acid amide hydrolase inhibitors enlisting proteome-wide selectivity screening: concurrent optimization of enzyme inhibitor potency and selectivity.
The Scripps Research Institute
Heterocyclic sulfoxide and sulfone inhibitors of fatty acid amide hydrolase.
The Scripps Research Institute
Discovery and Development of a Potent, Selective, and Orally Bioavailable CHK1 Inhibitor Candidate: 5-((4-((3-Amino-3-methylbutyl)amino)-5-(trifluoromethyl)pyrimidin-2-yl)amino)picolinonitrile.
Zhejiang University
Discovery of SK-575 as a Highly Potent and Efficacious Proteolysis-Targeting Chimera Degrader of PARP1 for Treating Cancers.
West China Hospital of Sichuan University
Development of selective mono or dual PROTAC degrader probe of CDK isoforms.
Sichuan University and Collaborative Innovation Center of Biotherapy
Structure-Based Design of Tetrahydroisoquinoline-7-carboxamides as Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.
Chinese Academy of Sciences
Amino-caprolactam derivatives as gamma-secretase inhibitors.
Bristol-Myers Squibb Research and Development
Tetrahydroisoquinoline-7-carboxamide Derivatives as New Selective Discoidin Domain Receptor 1 (DDR1) Inhibitors.
Jinan University
Synthesis, activity evaluation, and docking analysis of barbituric acid aryl hydrazone derivatives as RSK2 inhibitors.
East China University of Science and Technology